

Fresenius Medical Care

The World's Leading Renal Therapy Company



Business Update

Financial Highlights Q4 / FY 2002





Outlook

2002 – Key Accomplishments

- Introduced UltraCare[™] Concept in our North American clinics
- Continued above-market growth in worldwide product business
- Achieved major breakthroughs in 1996 merger-related legal issues including Fraudulent Conveyance (FC)
- Adjusted to Latin American currency environment to continue profitable growth
- Generated Outstanding Free Cash Flow





- Improving Operating Margin in North America
- Positive UltraCare[™] Outcome Data
- Stable reimbursement environment in North America
- Significant Global Growth Opportunities in Peritoneal Dialysis




Improving Operating Margin North America

2002 Achieving single-use cost neutrality

- New staffing model delivers efficiencies
- Medical supply costs differential < \$1/treatment</p>

2003 Upgrading North American operating performance


- New management structure
- Streamlining of less efficient clinics
- Manufacturing / Logistics cost reduction program



Fresenius Medical Care

Positive UltraCare™ NR Outcome Data

Significantly better medical outcomes which improve with time on UltraCare™ NR



Case Mix:	age, gender, race, diabetes, years on dialysis
Lab:	e.g. albumin, bicarbonate, blood Ph, body surface area, calcium, creatinine, iron, KT, phosphorus, ferritin etc.
Source:	Preliminary retrospective analysis of Company data generated from roll-out of UltraCare [™] NR program.



Stable Reimbursement environment in North America

Near term: stable to positive

- No Medicare increase in 2003 as expected
- MedPac¹ proposed 1.6% composite rate increase for 2004

Strategic: opportunity for new renal services

CMS² Open Door Forum – Disease Management (DM) Demonstration project

Opportunity to establish DM in Medicare environment



¹ Medicare Payment Advisory Commission (MedPac), advises the U.S. Congress on issues affecting the Medicare program (www.medpac.gov)

² Centers for Medicare&Medicaid Services (CMS) is a federal agency within the U.S. Department of Health and Human Services. CMS was formerly known as the Health Care Financing Administration (HCFA) (www.cms.gov)

Significant Global Growth Opportunities in Peritoneal Dialysis (PD)


Peritoneal Dialysis (PD)

- Treatment Modality for ~11% of global patients
- Dominant treatment in selected regional markets and patient situations

Our market position

- No. 2 worldwide supplier
- Complete product range and global manufacturing presence
- Growing clearly above market


FY 2002: above-market growth in PD



Fresenius Medical Care

2002 Revenue Growth by Segment


Total revenues \$5,084 million +5% (6% constant currency=cc)







Revenue by Business Unit FY 2002 and Q4



Fresenius Medical Care


Legal Update – Fraudulent Conveyance (FC) & W.R. Grace Bankruptcy

Outstanding success by achieving definitive agreement and confirming adequacy of accrued reserve

- Released from FC claims and potential future W.R. Grace related exposure
 - Indemnified against all W.R. Grace taxes
 - Released from responsibility to handle W.R. Grace tax issues
 - No admission of liability has been or will be made



Legal Update – Fraudulent Conveyance (FC) & W.R. Grace Bankruptcy





Fresenius Medical Care Global Position:

Achieved distinct market differentiation in both product and services

Vertical Integration

Products

• Expanded network of plants and manufacturing capacity for both HD and PD in Europe, Asia, Latin America and North America

 Introduced innovative new product technologies for machines and dialyzers

Patient Services

- Expanded network of clinics worldwide
- Introduced and rolled out UltraCare ™NR in North American clinics
- Participate in North America new reimbursement paradigm





Financials 2002

- Key figures Q4 and FY 2002
- Update: Financing Activities
- Financial Outlook





Financial Highlights FY 2002

	As reported	As reported ¹		
\$ millions	FY [,] 02	FY [,] 01	% Growth	% Growth constant currency
Net revenues	5,084	4,859	5	6
EBIT	695	644	8	7
Goodwill adjusted		765		
EAT	302	245	23	
Goodwill adjusted		347		
EPS per Ord. (\$)	3.12	2.53	23	
Goodwill adjusted		3.60		

¹ Excluding special charge of \$258m (\$177m net of taxes) and related expenses of \$7m in 2001 (\$4m, net of taxes)




Financial Highlights Q4 2002

	As reported	As reported ¹		
\$ millions	Q4 [,] 02	Q4 [,] 01	% Growth	% Growth constant currency
Net revenues	1,358	1,270	7	8
EBIT	184	152	21	18
Goodwill adjusted		179		
EAT	82	60	36	
Goodwill adjusted		85		
EPS per Ord. (\$)	0.85	0.62	36	
Goodwill adjusted		0.88		

¹ Excluding special charge of \$258 million in 2001 (\$177 million, net of taxes)



Days Sales Outstanding (DSO)



Fresenius Medical Care

Cash Flow FY 2002


in \$ millions	FY [,] 02	FY [,] 01
Net cash provided by operating activities	550	424
Capital expenditure (net)	(201)	(251)
Free Cash Flow	349	173
Acquisitions	(80)	(217)
Free Cash Flow after acquisitions	269	(43)

FY 2002 Cash Generation

in % of total revenue	2001	2002	
Cash from operations	8.7%	10.8%	1
Capital expenditure 1 (net)	5.2%	3.9%	
Free Cash Flow	3.5%	6.9%	1
Acquisitions		\$ 80 m	
Dividend		\$ 77 m	
Free CF available for debt reduction		\$ 192 m	



Dividend Proposal: 6th consecutive increase



¹ Proposal of the Managing Board to the Supervisory Board for shareholder approval at the AGM on May 22, 2003

Capital Expenditure split 2002 Total Capital Expenditure \$ 201 million Investment in Growth Investment by business segment **Products** Expansion \$92 m \$ 105 m 46% 52%

Services \$ 109 m

54%




48%

Maintenance

\$96 m

Acquisition Expenditure 2002







in \$ millions		Dec. 31, 02
EBITDA		916
Debt	<u>Sept. 30, 2002:</u> 2,906	
+ CapEx	45	
+ Acquisitions	7	
+ Fx-effects	43	
- Others	13	
- Cash from Operations	155	2,833
Total debt / EBITDA		3.09



Senior Credit Agreement

- Closed: February 21, 2003
- Tranches: \$500 million revolving credit facility ;

\$ 500 million term loan A ;

- \$ 500 million term loan B for inst. Investors
- Maturity:

October 31, 2007 for the revolving credit facility and term loan A ; 7 years for term loan B

Amortization:

\$ 25 million per quarter for term loan A
beginning in Q3 2004 ;
1% per year for term loan B



Fiscal Year 2002		
	2002 Target announced in July, 2002	FY 2002
Revenue growth (constant currency)	~ 6%	6%
Earnings after tax 1	~ \$ 300 m	\$ 302 m
CapEx	~ \$ 220 m	\$ 201 m
Free Cash Flow	> \$ 200 m	\$ 349 m
Acquisition spending	~ \$ 100 m	\$ 80 m
Free Cash Flow after acquisitions	> \$ 100 m	\$ 269 m

¹ before extraordinary charge of \$ 12 m after taxes for the early redemption of Trust Pref. Securities



Confirmed Financial Outlook 2003

Revenue growth (constant currency)

Earnings after tax ¹ growth

Capital Expenditure

Acquisition spending

Mid single digit

High single / low double digits

~ \$220 m

< \$100 m



¹ based on 2002 EAT before extraordinary item

Mid-term Financial Targets







Safe Harbor Statement

This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in the Company's reports filed with Securities and Exchange Commission.





Fresenius Medical Care

The World's Leading Renal Therapy Company